Revolution Medicines' High-Stakes Bet on Conquering RAS Cancers

REDWOOD CITY, CA – February 25, 2026 – Revolution Medicines today painted a picture of aggressive expansion and high-stakes clinical ambition, outlining significant progress across its broad pipeline of cancer therapies aimed at the notoriously difficult-to-drug RAS family of proteins. While reporting widening financial losses for 2025, the company underscored a robust cash position and a clear focus on a series of pivotal late-stage trials that could redefine treatment for some of the deadliest cancers.

The announcement positions the company for a transformative period, with a key data readout for its leading drug candidate, daraxonrasib, in pancreatic cancer expected in the first half of 2026. This, combined with an expanding roster of Phase 3 studies, places Revolution Medicines at the forefront of the battle against RAS-addicted tumors, a group of cancers that have long thwarted therapeutic development.

“Our focus remains on executing high-quality clinical programs and leveraging our innovation platform to discover and develop potentially groundbreaking approaches aimed at improving outcomes for patients with RAS-addicted cancers,” said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, in a statement.

A Multi-Front War on Cancer's Toughest Targets

At the heart of the company's strategy is an unprecedentedly broad and deep pipeline of RAS(ON) inhibitors, compounds designed to block the active, cancer-driving form of the RAS protein. The scale of this effort is substantial, with five ongoing Phase 3 trials and three more planned to launch this year.

The company's efforts are sharply focused on cancers with dire prognoses and significant unmet needs, particularly pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC).

For pancreatic cancer, a disease with a grim five-year survival rate, Revolution Medicines is advancing two different drugs. The global Phase 3 trial for daraxonrasib in patients with second-line metastatic disease (RASolute 302) is now fully enrolled, setting the stage for a highly anticipated data readout in the first half of 2026. Success here could offer a vital new targeted therapy for patients who have exhausted initial chemotherapy options. The company is also evaluating daraxonrasib in both first-line and post-surgery settings.

Simultaneously, its G12D-selective inhibitor, zoldonrasib, has entered a Phase 3 trial (RASolute 305) for first-line metastatic pancreatic cancer. This is particularly noteworthy as it targets a specific mutation, RAS G12D, which is common in PDAC but currently lacks any approved targeted therapy. Encouraging initial data from a combination study of zoldonrasib with chemotherapy showed a 63% partial response rate, fueling optimism for this new approach.

In the lung cancer arena, enrollment for RASolve 301, a Phase 3 trial of daraxonrasib in previously treated NSCLC, is expected to be substantially complete this year. Further strengthening its lung cancer program, zoldonrasib was recently awarded Breakthrough Therapy Designation by the FDA for previously treated NSCLC patients with a RAS G12D mutation, marking the third such designation for the company's RAS(ON) inhibitors. This status is reserved for drugs that may demonstrate substantial improvement over available therapy and is intended to expedite development and review.

The Billion-Dollar Price of Progress

This ambitious clinical strategy comes at a significant cost. Revolution Medicines reported a net loss of $1.1 billion for 2025, a substantial increase from the $600.1 million loss in 2024. The surge is driven by escalating research and development expenses, which nearly doubled to $987.3 million, and a sharp rise in administrative costs as the company prepares for potential commercial launches.

Looking ahead, the company projects its GAAP operating expenses for 2026 will be between $1.6 and $1.7 billion. This formidable burn rate reflects the immense financial commitment required to run multiple large-scale, global Phase 3 trials simultaneously.

However, the company appears well-capitalized to weather this spending. It ended 2025 with over $2.0 billion in cash, cash equivalents, and marketable securities. This financial strength is significantly bolstered by an innovative funding partnership with Royalty Pharma, which provides access to up to $2 billion in capital. The structure of the deal, which includes synthetic royalty monetization and secured debt, gives Revolution Medicines substantial financial runway and flexibility while allowing it to retain full control over its development and commercialization strategy. This arrangement effectively provides the fuel needed to drive its extensive pipeline toward the finish line without immediate pressure to seek additional equity financing.

Forging a New Path with Novel Science

Revolution Medicines' core scientific premise differentiates it from many competitors. Its inhibitors are designed to bind to the active RAS(ON) state, whereas the first generation of approved KRAS G12C inhibitors, such as sotorasib and adagrasib, target the inactive state. This fundamental difference in mechanism could prove advantageous in delivering more potent or durable responses.

The company is also looking beyond its current late-stage assets. Acknowledging that drug resistance is an inevitable challenge in cancer therapy, the firm has already unveiled a new class of RAS(ON) inhibitors designed specifically to overcome acquired resistance. Preclinical data for a compound from this class, RM-055, showed it could drive deep tumor regressions in models that had become resistant to a prior RAS inhibitor. A Phase 1 trial for the first compound from this next-generation platform is planned to begin in the fourth quarter of this year.

This forward-looking strategy, combined with a portfolio of clinical collaborations to test its inhibitors with other targeted agents, demonstrates a comprehensive approach to tackling the complexity of RAS-driven cancers. As the company barrels toward multiple pivotal data readouts in 2026, the coming months will be critical in determining whether its massive investment and novel scientific approach can translate into a new era of treatment for patients.